Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Feasibility, safety, and preliminary efficacy of very low-volume interval training in advanced cancer patients
Reljic D, Herrmann HJ, Jakobs B, Dieterich W, Mougiakakos D, Neurath MF, Zopf Y
Medicine and Science in Sports and Exercise 2022 Nov;54(11):1817-1830
clinical trial
5/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: No; Baseline comparability: No; Blind subjects: No; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: Yes; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*

PURPOSE: High-intensity interval training (HIIT) has been shown to improve cardiorespiratory fitness (CRF) and health-related outcomes in various chronic diseases, including cancer. However, data on feasibility and efficacy of HIIT in advanced cancer patients are still sparse, presumably due to safety concerns, like suspected immunosuppression after vigorous exercise. This randomized, sham-intervention controlled study aimed to investigate feasibility, safety and preliminary efficacy of very low-volume HIIT (LOW-HIIT) in advanced cancer patients. METHODS: Twenty-seven patients (55.4 +/- 13.2 yr) with different advanced cancers (UICC III/IV) were randomly allocated to LOW-HIIT (n = 13), consisting of 5x1 min cycle ergometer intervals (14 min/session total duration) at 80 to 95% HRpeak (2 sessions/week for 12 weeks), or a sham-intervention (n = 14) performing light physical mobilization exercises (SHAM). Primary outcomes were attrition and attendance rates, with values of <= 25% and >= 80%, respectively, considered acceptable. Secondary outcomes were safety, protocol fidelity, physiological (including CRF measures) and patient-reported outcomes (including fatigue and quality of life). RESULTS: One of 13 patients (8%) receiving LOW-HIIT dropped out. Mean attendance rate was approximately 93%. The prescribed minimum exercise intensity was consistently reached by all patients. LOW-HIIT was well-tolerated and not associated with any serious adverse event nor with increased infection susceptibility. There were no biochemical signs of acute immunosuppression after LOW-HIIT. Contrarily, differentiation and degranulation of natural killer cells was acutely increased post-exercise. LOW-HIIT improved CRF measures including peak oxygen uptake, self-reported fatigue, physical and social functioning. No significant changes occurred in the SHAM group. CONCLUSIONS: LOW-HIIT can be regarded as feasible and safe in advanced cancer patients. Our preliminary data indicate favorable acute effects on NK-cells and beneficial chronic adaptations in CRF, fatigue and aspects of QoL.

Full text (sometimes free) may be available at these link(s):      help